During this segment of Cell & Gene Live, Miguel Forte, M.D., Ph.D., CEO and Co-Founder, Kiji Therapeutics; Michael Schuster, Director of Business Development, Mesoblast; and Edward Ahn, Ph.D., CEO and Director, MEDIPOST Inc. share how recent negative iPSC-derived MSC clinical data should be interpreted, including the potential impact of trial design, patient selection, dosing, and the challenges of demonstrating efficacy in difficult indications.